These antiviral medications – acyclovir, famciclovir, and valacyclovir – share a common mechanism: they act as nucleoside analogs. They mimic the natural building blocks of viral DNA, specifically guanosine. The key difference lies in their metabolic pathways.
Acyclovir: A Direct Approach
Acyclovir itself requires viral enzymes for activation. Specifically, it needs viral thymidine kinase to transform it into acyclovir monophosphate. Cellular enzymes subsequently convert it to the active triphosphate form, which inhibits viral DNA polymerase, halting viral DNA replication.
Famciclovir and Valacyclovir: Prodrugs with Advantages
Famciclovir and valacyclovir are prodrugs, meaning they are inactive until metabolized in the body. Famciclovir is converted to penciclovir, which then follows a similar pathway to acyclovir, requiring viral thymidine kinase for activation. Valacyclovir undergoes rapid conversion to acyclovir, offering superior bioavailability compared to acyclovir itself. This means higher concentrations of the active antiviral drug are achieved in the body.
Therefore, while all three drugs target viral DNA polymerase, their differing absorption and metabolic profiles influence their overall antiviral activity and clinical applications. Valacyclovir, due to its higher bioavailability, often requires less frequent dosing.
Key Differences Summarized
Acyclovir: Direct action, lower bioavailability, more frequent dosing.
Famciclovir: Prodrug, converted to penciclovir, intermediate bioavailability.
Valacyclovir: Prodrug, converted to acyclovir, high bioavailability, less frequent dosing.
